HK$10.90
0.09%
Hong Kong, Oct 12, 04:08 pm HKT. Closed.
ISIN
HK0000658531
Symbol
2096

Simcere Pharmaceutical Group Stock price

HK$10.90
-0.49 4.30% 1M
-2.83 20.61% 6M
-1.07 8.94% YTD
-1.64 13.08% 1Y
+4.14 61.24% 3Y
+3.77 52.88% 5Y
-0.08 0.73% 10Y
-0.08 0.73% 20Y
Hong Kong, Closing price Mon, Oct 12 2026
+0.01 0.09%
ISIN
HK0000658531
Symbol
2096
Industry

Is Simcere Pharmaceutical Group a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,114 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$28.2b
Enterprise Value
HK$24.9b
Net debt
positive
Cash
HK$4.7b
Shares outstanding
2.6b
Valuation
P/E
15.1
P/S | estimate
2.8 | 2.4
EV/Sales | estimate
2.4 | 2.1
EV/FCF | ex SBC
- | -
P/B
2.6
Dividends
DPS
HK$0.21
Yield 1Y | 5Y
1.9% | 2.0%
Growth 1Y | 5Y
18.4% | 2.8%
Payout 1Y | 3Y
27.3% | 40.5%
Increased
1 Year
Financials
Revenue | estimate
HK$10.2b | HK$11.9b
EBITDA
-
EBIT
HK$2.1b
Net Income
HK$1.8b
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
22.8% | 31.7%
EBITDA
-
EBIT
40.5%
Net Income
81.1%
Free Cash Flow
-
Margin
Gross
82.9%
EBITDA
-
EBIT
20.2%
Net
18.0%
Free Cash Flow | ex SBC
- | -
Financial Health
Equity Ratio
63.9%
Return on Equity
14.3%
ROCE
15.3%
ROIC
17.6%
Debt/Equity
0.1
More
EPS
HK$0.7
FCF per Share
-
Short interest
-
Employees
7k
Rev per Employee
HK$1.3m

Simcere Pharmaceutical Group Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Simcere Pharmaceutical Group forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Simcere Pharmaceutical Group forecast:

Buy
90%
Hold
10%

Financial data from Simcere Pharmaceutical Group

Jun '26
+/-
%
10,234 10,234
23% 23%
100%
- Direct Costs 1,754 1,754
11% 11%
17%
8,480 8,480
26% 26%
83%
- Selling and Administrative Expenses 4,608 4,608
20% 20%
45%
- Research and Development Expense 2,059 2,059
18% 18%
20%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 2,065 2,065
40% 40%
20%
Net Profit 1,840 1,840
81% 81%
18%

In millions HKD.

Don't miss a Thing! We will send you all news about Simcere Pharmaceutical Group directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Simcere Pharmaceutical Group Ltd. engages in the research, development, manufacturing, and sale of pharmaceutical products. The firm's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The firm also produces various drugs, including Endostar used for oncology. The firm is also involved in providing promotion services for third-party drugs sold by medical institutions. The firm mainly conducts its businesses in the domestic market and overseas markets.

Head office Hong Kong
CEO Mr. Ren
Employees 7,038
Website www.simcere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today